Strategic Implications for Academia on Clinical Research

Fellow at Center for Research and Development Strategy
Visiting associate professor at Keio University
September 12, 2009
Yuji Yamamoto, MD, MBA
Center for Research and Development Strategy (CRDS)

- Established on 1, July 2003 in JST (Japan Science and Technology Agency)
- Make “Strategic Proposals” on R&D to facilitate scientific and technological activities in Japan
- Help JST and the relevant ministries of the Japanese Government develop funding strategy, reform regulations and support R&D
CRDS clinical research unit activities

CRDS

Policy Proposals

Ministry of Health, Labour and Welfare (MHLW)
Ministry of Economy, Trade and Industry (METI)
Council for Science and Technology Policy (CSTP)
Ministry of Education, Culture, Sports, Science and Technology (MEXT)

Regulatory reform  Funding  National R&D plan

Japan Science and Technology Agency
Streamlining Value chain of R&D – Concept of ICR

- Broadly-defined TR
- Narrowly-defined TR
- FDA Critical Path Research
- NIH Roadmap Plan

1/20,000 & $1000mil Project

- 2-3yrs
- 3-5yrs
- 5-10yrs
- 1-2yrs

Integrative Celerity Research (ICR)
Points to consider to implement ICR

- Goals – stakeholders’ needs & interest
  - Science and technology R&D value chain

- Regulations around health care R&D
  - Pharmaceutical affairs act, Guidelines...
  - Patent act

- Funding
  - Time value of money

- Collaboration/competition with others
  - Staff recruiting and team structure
  - No “NIH syndrome”

No success without strategic and managerial view point....
Strategic Implications – Managed R&D

- Set vision and goal-oriented mission for your R&D
- Measure and report efficiency and effectiveness of your activities
- Access and seek for expertise advice for important but less counted aspects
- Practice, practice and practice!